Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study of the Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as a New imMUne Prognostic Biomarker in Breast Cancer Treated by NEOadjuvant Chemotherapy

NCT01513408 is registered in ClinicalTrials.gov with Centre Georges Francois Leclerc as lead sponsor.

NCT NCT01513408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01513408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study of the Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as a New imMUne Prognostic Biomarker in Breast Cancer Treated by NEOadjuvant Chemotherapy
Lead sponsor
Centre Georges Francois Leclerc
Phase
Not applicable
Overall status
Unknown status
Start date
May 31, 2012
Completion date
October 31, 2025
Enrollment
500 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer